Member News

Protein Society recognizes Gardner, Gestwicki

ASBMB Today Staff
June 19, 2023

American Society for Biochemistry and Molecular Biology members Kevin Gardner and Jason Gestwicki have received 2023 awards from the Protein Society.
 

Kevin Gardner
Jason Gestwicki

Gardner won the Stein & Moore Award, which recognizes eminent leaders in protein science who have made sustained high-impact research contributions to the field. Gestwicki received the Emil Thomas Kaiser Award, which recognizes a recent and highly significant contribution or application of chemistry to the study of proteins.

Gardner is a professor of chemistry and biochemistry at the City College of New York and City University of New York Graduate Center as well as and the director of the Structural Biology Initiative at the CUNY Advanced Science Research Center. He studies the structure, dynamics and function of ligand-regulated protein interaction domains from bacteria, plants and humans to develop innovative optogenetic tools and cancer therapies. Gardner has won many honors for his research and mentoring including the Biophysical Society Biophysics of Health and Disease Award. He is a member of the ASBMB Public Affairs Advisory Committee.

Gestwicki is a professor of pharmaceutical chemistry and associate director of the institute for neurodegenerative diseases at the University of California, San Francisco. His research focuses on molecular chaperones and developing innovative tools and approaches to target diseases of protein misfolding. The group recently published a research article on the structure–activity relationships of the human 20S proteasome activators.

Gardner, Gestwicki and other Protein Society award recipients will be honored in July at the society’s annual symposium in Boston.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

ASBMB members recognized as Allen investigators
Member News

ASBMB members recognized as Allen investigators

July 14, 2025

Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.

AI can be an asset, ASBMB educators say
Advice

AI can be an asset, ASBMB educators say

July 9, 2025

Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.

ASBMB undergraduate education programs foster tomorrow’s scientific minds
Feature

ASBMB undergraduate education programs foster tomorrow’s scientific minds

July 8, 2025

Learn how the society empowers educators and the next generation of scientists through community as well as accreditation and professional development programs that support evidence-based teaching and inclusive pedagogy.

Honors for Gagna and Sundquist
Member News

Honors for Gagna and Sundquist

July 7, 2025

Claude Gagna is being honored for the diagnostic tool he developed that uses AI to streamline diagnostics. Wesley Sundquist is being honored for his role in finding that HIV’s capsid was a target for treatment.